Crossmark

Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation

Crossref DOI link: https://doi.org/10.1186/s13075-017-1419-5

Published Online: 2017-09-26

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Challa, Divya N.

Kvrgic, Zoran

Cheville, Andrea L.

Crowson, Cynthia S.

Bongartz, Tim

Mason, Thomas G. II

Matteson, Eric L.

Michet, Clement J. Jr

Persellin, Scott T.

Schaffer, Daniel E.

Muskardin, Theresa L. Wampler

Wright, Kerry

Davis, John M. III
Funding

Funding for this research was provided by:

Larry and Ruth Eaton Family Career Development Fund in Innovative Rheumatoid Arthritis Research

National Center for Advancing Translational Sciences (UL1 TR000135)
License Information

Text and Data Mining valid from 2017-09-26
More Information

Article History

Received: 26 May 2017

Accepted: 4 September 2017

First Online: 26 September 2017

Ethics approval and consent to participate

: The Mayo Clinic Institutional Review Board (IRB) approved the study (study no. 14-003798). For the retrospective study, the IRB granted a waiver of informed consent. Study personnel verified that all patients granted authorization for use of their medical records for research as required by Minnesota state law. All participants in the prospective substudy provided written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.